Compare DexCom, Inc. (DXCM) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs W W Grainger Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while W W Grainger Inc trades at $1,305.49 (market cap $61.32B). The key difference: W W Grainger Inc is the larger of the two by market cap, and W W Grainger Inc pays a 0.77% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | GWW | |
|---|---|---|
Market Cap | $33.79B | $61.32B |
Sector | Health | Technology |
52-Week High | $89.53 | $1.40K |
52-Week Low | $54.84 | $918.18 |
Enterprise Value | $33.24B | $63.53B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
W.W. Grainger (GWW) trades at $1,304.88, up 0.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised its full-year outlook. Revenue grew to $18.8 billion in 2026, with a net income margin of 9.92%. Analyst consensus is a 'Hold' with a $1,320 price target, though institutional sentiment is mixed amid high valuation multiples.
GWW's earnings momentum and market share gains support upside potential, but elevated P/E of 33.19 and bearish technicals pose near-term risks. Investors should weigh robust fundamentals against valuation concerns and macroeconomic pressures affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
